Zacks Research Has Negative Forecast for Amgen Q3 Earnings

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Zacks Research cut their Q3 2025 EPS estimates for Amgen in a research report issued on Wednesday, December 4th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $5.21 per share for the quarter, down from their prior estimate of $5.22. The consensus estimate for Amgen’s current full-year earnings is $19.51 per share. Zacks Research also issued estimates for Amgen’s Q3 2026 earnings at $5.42 EPS.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the prior year, the business earned $4.96 EPS. The firm’s revenue was up 23.2% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Royal Bank of Canada cut their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a report on Wednesday, November 27th. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Sanford C. Bernstein assumed coverage on Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price on the stock. Finally, Barclays raised their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $323.05.

Amgen Price Performance

Amgen stock opened at $272.58 on Monday. The business has a 50 day simple moving average of $306.58 and a 200-day simple moving average of $315.86. Amgen has a 12 month low of $257.80 and a 12 month high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock has a market capitalization of $146.52 billion, a PE ratio of 34.90, a price-to-earnings-growth ratio of 3.08 and a beta of 0.55.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.30%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Hedge Funds Weigh In On Amgen

Hedge funds have recently bought and sold shares of the stock. Capital Performance Advisors LLP purchased a new stake in Amgen during the 3rd quarter worth about $25,000. Strategic Financial Concepts LLC purchased a new stake in shares of Amgen during the second quarter worth about $26,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the third quarter valued at approximately $29,000. Hershey Financial Advisers LLC purchased a new position in shares of Amgen during the second quarter valued at approximately $30,000. Finally, nVerses Capital LLC acquired a new stake in Amgen during the second quarter worth approximately $31,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.